Hospice Care for Patients with Advanced Cancer Has Significant Impact on Quality of Life
the Cancer Therapy Advisor take:
In a new study published recently in the Journal of the American Medical Association, researchers from Brigham and Women’s Hospital in Boston, Massachusetts, examined hospice care in terms of its impact on the intensity of treatment for advanced cancer, specifically in a sample of elderly patients on Medicare.
They discovered that those patients who were enrolled in hospice care had lower rates of health care utilization, and their costs for care were less during their last year of life. Alternatively, those patients who did not enroll in hospice received significantly more aggressive care in their last year of life, most of which was related to acute complications of their treatment, such as infections or organ failure.
In addition, 74% of those patients who did not enroll in hospice care died in hospitals and nursing facilities, whereas only 14% of those that were in hospice died in a hospital setting. The cost of care for patients not in hospice also rose sharply during the last year of life.
The investigators emphasized that these results show that doctors need to have more honest, open discussions about the goals for end-of-life care, particularly as it relates to the patients’ quality of life and treatment decisions.
Patients enrolled in hospice care had lower rates of healthcare utilization.
More patients with cancer use hospice today than ever before, but there are indications that care intensity outside of hospice is increasing, and length of hospice stay decreasing.
Researchers at Brigham and Women's Hospital (BWH) examined how hospice affects health care utilization and costs and found that in a sample of elderly Medicare patients with advanced cancer, hospice care was associated with significantly lower rates of both health care utilization and total costs during the last year of life. Ultimately, those who chose hospice were five times less likely to die in hospitals and nursing homes.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- Combination Abiraterone Acetate, Radium-223 Not Recommended in CRPC With Bone Mets
- Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib
- Higher Baseline AFP Linked to Greater Benefit With Cabozantinib in Hepatocellular Carcinoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- A Big BiTE: Tetravalent BiTE Highly Potent in HER2-positive Breast Cancer Models